期刊
CURRENT TREATMENT OPTIONS IN ONCOLOGY
卷 19, 期 12, 页码 -出版社
SPRINGER
DOI: 10.1007/s11864-018-0584-3
关键词
Ovarian cancer; Immunotherapy; Immune checkpoint inhibitors; Cancer vaccine; Adoptive immunotherapy; PD1; PD-L1; PD-L2; CTLA-4; Nivolumab; Ipilimumab; Pembrolizumab; Avelumab; Atezolizumab; PARP inhibitors; BRCA 1; 2 mutation; Microsatellite instability; Bevacizumab; Anti-angiogenic; NY-ESO; MAGE; p53; Mirvetuximab soravtansine; Folate receptor alpha; Folate-binding protein; TILS; CAR-T cells; NK cells; T cells; HER2; Mesothelin
类别
Opinion statementThe rise of immunotherapy is the greatest advance in oncology to occur over the last several years, but applications in gynecologic malignancies lag behind other tumors. The term immunotherapy envelops monoclonal antibodies as receptor mediators, including immune checkpoint inhibitors (ICPI), cancer vaccines, and adoptive immunotherapies alone or in combination with other therapeutic approaches. The purpose of this review is to summarize the status of immunotherapy trials in ovarian cancer and to specifically highlight data published in the last 1-2years.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据